2132.5000 4.80 (0.23%)
NSE Sep 12, 2025 15:31 PM
Volume: 615.4K
 

HDFC Securities
Buoyant performance of the US, Russia/CIS and API segments led to a 16% YoY growth in the top line. However, a sharp increase (up 21%YoY) in the staff cost due to incremental incentives kept EBITDA margins below expectations at 18.3% in 2Q. PAT growth too was sluggish at 11% YoY only.
Glenmark Pharmaceuticals Ltd. is trading above all available SMAs
More from Glenmark Pharmaceuticals Ltd.
Recommended